Skip to main content
SpringerLink
Log in

Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

This study aimed to investigate the efficacy of docetaxel in castration-resistant prostate cancer (CRPC) patients with intraductal carcinoma of the prostate (IDC-P).

Patients and methods

We retrospectively identified 79 CRPC patients with distant metastasis at initial diagnosis from June 2002 to January 2014. All patients received initial androgen deprivation therapy and 46 received docetaxel chemotherapy after progressing to CRPC. The primary outcome of interest was cancer-specific survival (CSS) from the time of CRPC diagnosis. The Cox regression model was used to confirm whether IDC-P and docetaxel would act as independent factors for prognosis.

Results

IDC-P was found in 62 of 79 patients. The median CSS in the IDC-P-present group was 18.2 versus 45.6 months in the IDC-P-absent group (HR 2.67; 95% CI 1.18 to 6.06; P = 0.019). Docetaxel was administered to 36 patients with IDC-P and 10 patients without IDC-P, with a median CSS of 20.5 versus 53.2 months, respectively (HR 2.98; 95% CI 1.02 to 8.64; P = 0.044). Multivariate analysis demonstrated that the presence of IDC-P and docetaxel were independent prognostic factors for CSS (P = 0.026 and 0.005, respectively) and overall survival (OS) (P = 0.029 and 0.001, respectively).

Conclusion

The presence of IDC-P is an independent prognostic factor in CRPC patients with distant metastases and IDC-P in needle biopsies at the time of initial diagnosis. Docetaxel may prolong CSS and OS in CRPC patients with distant metastases and IDC-P in needle biopsies at the time of initial diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kovi J, Jackson MA, Heshmat MY (1985) Ductal spread in prostatic carcinoma. Cancer 56:1566–1573

    Article  PubMed  CAS  Google Scholar 

  2. McNeal JE, Yemoto CE (1996) Spread of adenocarcinoma within prostatic ducts and acini: morphologic and clinical correlations. Am J Surg Pathol 20(7):802–814

    Article  PubMed  CAS  Google Scholar 

  3. Guo CC, Epstein JI (2006) Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod Pathol 19:1528–1535

    Article  PubMed  Google Scholar 

  4. Kimura K, Tsuzuki T, Kato M et al (2014) Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 74:680–687

    Article  PubMed  Google Scholar 

  5. Kato M, Tsuzuki T, Kimura K et al (2016) The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. Mod Pathol 29:166–173

    Article  PubMed  CAS  Google Scholar 

  6. Zhao T, Liao B, Yao J et al (2015) Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer? Prostate 75:225–232

    Article  PubMed  CAS  Google Scholar 

  7. Morais CL, Han JS, Gordetsky J et al (2015) Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. Am J Surg Pathol 39:169–178

    Article  PubMed  PubMed Central  Google Scholar 

  8. Risbridger GP, Taylor RA, Clouston D et al (2015) Patient derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur Urol 67:496–503

    Article  PubMed  CAS  Google Scholar 

  9. Lindberg J, Kristiansen A, Wiklund P et al (2015) Tracking the origin of metastatic prostate cancer. Eur Urol 67:819–822

    Article  PubMed  Google Scholar 

  10. Epstein JI, Egevad L, Amin M et al (2016) The 2016 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 40:244–252

    PubMed  Google Scholar 

  11. Humphrey PA, Moch H, Cubilla AL et al (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol 70:106–119

    Article  PubMed  Google Scholar 

  12. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  13. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  PubMed  CAS  Google Scholar 

  14. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumors, 7th edn. Wiley, Oxford

    Google Scholar 

  15. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159

    Article  PubMed  PubMed Central  Google Scholar 

  16. Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65:467–479

    Article  PubMed  CAS  Google Scholar 

  17. Tsuzuki T (2015) Intraductal carcinoma of the prostate: a comprehensive and updated review. Int J Urol 22:140–145

    Article  PubMed  Google Scholar 

  18. Chen Z, Chen N, Shen P et al (2015) The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer. Prostate 75:1247–1254

    Article  PubMed  CAS  Google Scholar 

  19. Naito S, Tsukamoto T, Koga H et al (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II Trial in Japan. Jpn J Clin Oncol 38(5):365–372

    Article  PubMed  CAS  Google Scholar 

  20. Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Epstein JI, Zelefsky MJ, Sjoberg DD et al (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69:428–435

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Yushi Yamauchi, Department of Urology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan; Yoshie Moriya, Department of Urology, Komaki City Hospital, Komaki, Aichi, Japan; Yuta Sano, Department of Urology, Chukyo Hospital, Nagoya, Japan, for their help to investigate the present study.

Author information

Authors and Affiliations

  1. Department of Urology, Toyohashi Municipal Hospital, 50 Aza Hachiken Nishi, Aotake-Cho, Toyohashi, Aichi, 441-8570, Japan

    Akiyuki Yamamoto

  2. Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Masashi Kato, Yasuhito Funahashi, Naoto Sassa, Yoshihisa Matsukawa & Momokazu Gotoh

  3. Department of Urology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan

    Hirotaka Matsui & Ryohei Hattori

  4. Department of Urology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan

    Ryo Ishida

  5. Department of Urology, Chukyo Hospital, Nagoya, Japan

    Tohru Kimura

  6. Department of Urology, Komaki City Hospital, Komaki, Japan

    Osamu Kamihira

  7. Department of Surgical Pathology, School of Medicine, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan

    Toyonori Tsuzuki

Authors
  1. Akiyuki Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masashi Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hirotaka Matsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryo Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tohru Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuhito Funahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoto Sassa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshihisa Matsukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Osamu Kamihira
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ryohei Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Momokazu Gotoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Toyonori Tsuzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Akiyuki Yamamoto or Toyonori Tsuzuki.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to declare.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamamoto, A., Kato, M., Matsui, H. et al. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate. Int J Clin Oncol 23, 584–590 (2018). https://doi.org/10.1007/s10147-017-1235-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1235-6

Keywords

Search

Navigation